Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

RATIONALE: Giving chemotherapy, such as fludarabine phosphate, busulfan, and cyclophosphamide, and total-body radiation therapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. It is not yet known whether low-dose chemotherapy and total-body radiation therapy is more effective than high-dose chemotherapy in treating patients with myelodysplastic syndrome or acute myeloid leukemia.

PURPOSE: This phase III trial is studying low-dose conditioning to see how well it works compared to high-dose conditioning followed by peripheral blood stem cell transplant in treating patients with myelodysplastic syndromes or acute myeloid leukemia

Study Overview

• Status: Completed
• Conditions: Recurrent Adult Acute Myeloid Leukemia; Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Secondary Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia in Remission; Childhood Acute Myeloid Leukemia in Remission; Childhood Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Childhood Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; de Novo Myelodysplastic Syndromes; Myelodysplastic Syndrome With Isolated Del(5q); Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
• Intervention / Treatment: Other: laboratory biomarker analysis; Drug: fludarabine phosphate; Other: flow cytometry; Drug: cyclophosphamide; Drug: methotrexate; Drug: cyclosporine; Other: pharmacological study; Drug: tacrolimus; Genetic: fluorescence in situ hybridization; Procedure: peripheral blood stem cell transplantation; Genetic: cytogenetic analysis; Drug: mycophenolate mofetil; Genetic: polymorphism analysis; Radiation: total-body irradiation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: busulfan

Detailed Description

OBJECTIVES:

I. Determine whether the conditioning intensity affects outcomes after HCT in patients with MDS or AML who have < 5% marrow myeloblasts at the time of HCT.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

Arm I (Nonmyeloablative regimen):

CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0.

TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0.

GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.

Arm II (Myeloablative regimen):

CONDITIONING: Patients are assigned to 1 of 2 treatment groups.

Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2.

Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4.

TRANSPLANTATION: Patients undergo PBSC infusion on day 0.

GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.

Treatment in both arms continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up periodically.

• Study Type: Interventional
• Enrollment (Actual): 25
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Saxony
    • Dresden, Saxony, Germany, 01307
      • Technical University Dresden
• United States
  • Colorado
    • Denver, Colorado, United States
      • HealthOne Presbyterian St. Lukes Medical Center
  • Georgia
    • Altanta, Georgia, United States, 30322
      • Emory University
  • New York
    • New York, New York, United States, 10021
      • Weill Cornell University
  • Utah
    • Salt Lake City, Utah, United States, 84112
      • University of Utah
  • Washington
    • Seattle, Washington, United States, 98109
      • Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
    • Seattle, Washington, United States, 98108
      • Veterans Administration Center-Seattle
  • Wisconsin
    • Milwaukee, Wisconsin, United States
      • Medical College Wisconsin

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 65 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Myelodysplastic syndrome (MDS) or transformed acute myelogenous leukemia (transformed from MDS)
• De novo acute myelogenous leukemia (AML) beyond first remission
• Intermediate or high risk de novo AML in first complete response (at FHCRC unrelated donor recipients only)
• Chemotherapy required prior to HCT for all patients:
• A) Interval between start of a cycle of cytoreductive chemotherapy and infusion of donor stem cells must be at least 30 days; chemotherapy received for disease maintenance will be allowed during this time period
• B) All patients must have < 5% myeloblasts based on marrow morphology performed within 21 days prior to start of conditioning regimen and at least 3-4 weeks after the start of pre-transplant cytoreductive chemotherapy
• C) All patients must have no circulating peripheral blood myeloblasts present based on morphologic analysis
• Age 65 years or under for patients with related donors; age 60 years or under for patients with unrelated donors
• HCT-Specific Comorbidity Index Score (HCT-CI) < 3
• Related donor (age > 12 years, nonsyngeneic) or unrelated donor, HLA phenotypically or genotypically identical at the allele level at A,B,C,DRQ1, and CBQ1
• DONOR: Related or unrelated donors who are genotypically or phenotypically matched by high resolution HLA typing (HLA-A, B, C, DRB1, and DQB1); class 1 single allele mismatch allowed
• DONOR: Patient and donor pairs homozygous at a mismatched allele in the graft rejection vector are considered a two-allele mismatch, i.e., the patient is A*0101 and the donor is A*0201, and this type of mismatch is not allowed
• DONOR: A positive anti-donor cytotoxic crossmatch or flow cytometric assay is an absolute donor exclusion at FHCRC/SCCA
• DONOR: Age >= 12 years
• DONOR: Donors must consent to PBSC mobilization with G-CSF and leukaphereses; bone marrow as a source of stem cells will not be allowed
• DONOR: Donor must have adequate veins for leukaphereses or agree to placement of central venous catheter (femoral, subclavian)

Exclusion Criteria:

• HIV seropositivity
• Fungal infections with radiographic progression after appropriate therapy for greater than one month
• Organ dysfunction
• Symptomatic coronary artery disease or ejection fraction < 35%
• DLCO < 65%, FEV1 < 65% or receiving supplementary continuous oxygen
• Liver function abnormalities: Patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, histology, and the degree of portal hypertension; patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded
• Karnofsky Performance Score < 70
• Lansky-Play Performance Score < 70 for pediatric patients
• Life expectancy severely limited (< 2 years) by disease other than MDS/AML
• Fertile men and women unwilling to use contraceptive techniques during and for 12 months following treatment
• Patients with active non-hematological malignancies except:
• A) Patients with follicular or low grade lymphoma will be eligible as long as they have not and do not require active treatment for control of their disease
• B) Patients with localized non-melanoma skin malignancies
• Patients with poorly controlled hypertension who are unable to have blood pressure stabilized below 150/90 mm Hg on standard medication
• Females who are pregnant or breastfeeding
• Patients with systemic, uncontrolled infections
• Active CNS disease as identified by positive CSF cytospin
• DONOR: Identical twin
• DONOR: Age < 12 years
• DONOR: Pregnancy
• DONOR: HIV seropositivity
• DONOR: Inability to achieve adequate venous access
• DONOR: Known adverse reaction to G-CSF

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm I (Nonmyeloablative regimen); CONDITIONING: Patients receive fludarabine phosphate IV on days -4 to -2 and undergo low-dose total-body irradiation on day 0. TRANSPLANTATION: Patients undergo allogeneic peripheral blood stem cell (PBSC) infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive cyclosporine every 12 hours on days -3 to 57 with taper on days 57-177 or cyclosporine every 12 hours on days -3 to 100 with taper on days 101-177. Patients also receive oral mycophenolate mofetil every 12 hours on days 0-27 or every 8 hours on days 0-40 with taper on days 41-96.	Other: laboratory biomarker analysis; Correlative studies; Drug: fludarabine phosphate; Given IV; Other Names: 2-F-ara-AMP; Beneflur; Fludara; Other: flow cytometry; Correlative studies; Drug: cyclosporine; Given IV or orally; Other Names: ciclosporin; cyclosporin; cyclosporin A; CYSP; Sandimmune; Other: pharmacological study; Correlative studies; Other Names: pharmacological studies; Genetic: fluorescence in situ hybridization; Correlative studies; Other Names: fluorescence in situ hybridization (FISH); Procedure: peripheral blood stem cell transplantation; Undergo transplantation; Other Names: PBPC transplantation; PBSC transplantation; peripheral blood progenitor cell transplantation; transplantation, peripheral blood stem cell; Genetic: cytogenetic analysis; Correlative studies; Drug: mycophenolate mofetil; Given orally; Other Names: Cellcept; MMF; Genetic: polymorphism analysis; Correlative studies; Radiation: total-body irradiation; Radiation; Other Names: TBI; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Undergo allogeneic transplantation
Experimental: Arm II (Myeloablative regimen); CONDITIONING: Patients are assigned to 1 of 2 treatment groups. Group A: Patients receive fludarabine IV once daily and oral busulfan four times daily or busulfan IV over 3 hours on days -5 to -2. Group B: Patients receive cyclophosphamide IV over 1-2 hours on days -3 and -2 and oral busulfan four times daily or busulfan IV over 3 hours on days -7 to -4. TRANSPLANTATION: Patients undergo PBSC infusion on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Patients receive tacrolimus IV continuously or orally every 12 hours on days -1 to 56 and taper on days 57-200. Patients also receive methotrexate IV on days 1, 3, 6, and 11.	Other: laboratory biomarker analysis; Correlative studies; Drug: fludarabine phosphate; Given IV; Other Names: 2-F-ara-AMP; Beneflur; Fludara; Other: flow cytometry; Correlative studies; Drug: cyclophosphamide; Given IV; Other Names: Cytoxan; Endoxan; CPM; CTX; Endoxana; Drug: methotrexate; Given IV; Other Names: amethopterin; Folex; methylaminopterin; Mexate; MTX; Other: pharmacological study; Correlative studies; Other Names: pharmacological studies; Drug: tacrolimus; Given IV or orally; Other Names: Prograf; FK 506; Genetic: fluorescence in situ hybridization; Correlative studies; Other Names: fluorescence in situ hybridization (FISH); Procedure: peripheral blood stem cell transplantation; Undergo transplantation; Other Names: PBPC transplantation; PBSC transplantation; peripheral blood progenitor cell transplantation; transplantation, peripheral blood stem cell; Genetic: polymorphism analysis; Correlative studies; Procedure: allogeneic hematopoietic stem cell transplantation; Undergo allogeneic transplantation; Drug: busulfan; Given IV or orally; Other Names: BSF; BU; Misulfan; Mitosan; Myeloleukon

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Overall Survival	At 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free Survival	IWG criteria was used to determine disease progression	After stem cell infusion to date of last follow up.
Non-relapse Mortality		At 100 days
Donor Cell Engraftment	Chimerism analysis was performed in patients who recieved nonmyeloablative tranplsnat. In this group the definition of engraftment was a CD3 count greater than 50%. In the myeloablative group, engraftment was defined as an absolute neutrophil count greater than 50%.	After stem cell infusion to day 28
Incidence of Disease Progression/Relapse	Disease progression/relapse was defined by IWG criteria	After stem cell infusion to date of last follow up.
Incidence and Severity of Acute and Chronic Graft-vs-host Disease		After transplantation

Collaborators and Investigators

• Sponsor: Fred Hutchinson Cancer Center
• Collaborators: National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
• Investigators: Principal Investigator: Bart Scott, Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study record dates

Study Major Dates

• Study Start: January 1, 2006
• Primary Completion (Actual): April 1, 2012
• Study Completion (Actual): October 1, 2014

Study Registration Dates

• First Submitted: May 2, 2006
• First Submitted That Met QC Criteria: May 2, 2006
• First Posted (Estimate): May 4, 2006

Study Record Updates

• Last Update Posted (Estimate): October 31, 2014
• Last Update Submitted That Met QC Criteria: October 23, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Disease Attributes; Disease; Bone Marrow Diseases; Hematologic Diseases; Neoplastic Processes; Precancerous Conditions; Syndrome; Myelodysplastic Syndromes; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Neoplasm Metastasis; Recurrence; Preleukemia; Myeloproliferative Disorders; Myelodysplastic-Myeloproliferative Diseases; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Antirheumatic Agents; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Dermatologic Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antifungal Agents; Reproductive Control Agents; Antitubercular Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Antibiotics, Antitubercular; Calcineurin Inhibitors; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Methotrexate; Tacrolimus; Mycophenolic Acid; Busulfan; Cyclosporine; Cyclosporins
• Other Study ID Numbers: 1992.00; P01CA078902 (U.S. NIH Grant/Contract); P01CA018029 (U.S. NIH Grant/Contract); P01HL036444 (U.S. NIH Grant/Contract); NCI-2010-00737 (Registry Identifier: CTRP (Clinical Trial Reporting Program)); K23HL084054 (U.S. NIH Grant/Contract)